Background of ICI & Highlights in Oncology
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Background of ICI & Highlights in Oncology
-
Narrated by:
-
By:
About this listen
- Immune-checkpoint inhibitors (ICIs) represent a significant breakthrough in the field of cancer over the last 10-15 years
- Multiple ICIs currently available as IV therapies (8 PD-1/PD-L1 agents approved since 2011
- Robust survival benefit seen with ICI across multiple tumor types
- IV ICI therapy requires line access and creates increased chair time
- Subcutaneous (SC) ICI options provide increased patient convenience and operational efficiencies
- SC products may increase nurse resources due to time spent administering
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.